A Multicenter, Open-label, Single-arm Study to Evaluate Long-term Safety, Tolerability, and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age with Childhood Absence Epilepsy or Juvenile Absence Epilepsy.